Diminished responses to mRNA-based SARS-CoV-2 vaccines in individuals with rheumatoid arthritis on immune modifying therapies
Samuel D. Klebanoff, Lauren B. Rodda, Chihiro Morishima, Mark H. Wener, Yevgeniy Yuzefpolskiy, Estelle Bettelli, Jane H. Buckner, Cate Speake, View ORCID ProfileMarion Pepper, View ORCID ProfileDaniel J. Campbell
doi: https://doi.org/10.1101/2023.01.03.23284167
Samuel D. Klebanoff
1Benaroya Research Institute, Seattle, WA
2Department of Immunology, University of Washington School of Medicine, Seattle, WA
Lauren B. Rodda
2Department of Immunology, University of Washington School of Medicine, Seattle, WA
Chihiro Morishima
3Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA
Mark H. Wener
3Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA
Yevgeniy Yuzefpolskiy
1Benaroya Research Institute, Seattle, WA
Estelle Bettelli
1Benaroya Research Institute, Seattle, WA
2Department of Immunology, University of Washington School of Medicine, Seattle, WA
Jane H. Buckner
1Benaroya Research Institute, Seattle, WA
2Department of Immunology, University of Washington School of Medicine, Seattle, WA
Cate Speake
1Benaroya Research Institute, Seattle, WA
Marion Pepper
2Department of Immunology, University of Washington School of Medicine, Seattle, WA
Daniel J. Campbell
1Benaroya Research Institute, Seattle, WA
2Department of Immunology, University of Washington School of Medicine, Seattle, WA

Data Availability
All data produced in the present study are available upon reasonable request to the authors
Posted January 10, 2023.
Diminished responses to mRNA-based SARS-CoV-2 vaccines in individuals with rheumatoid arthritis on immune modifying therapies
Samuel D. Klebanoff, Lauren B. Rodda, Chihiro Morishima, Mark H. Wener, Yevgeniy Yuzefpolskiy, Estelle Bettelli, Jane H. Buckner, Cate Speake, Marion Pepper, Daniel J. Campbell
medRxiv 2023.01.03.23284167; doi: https://doi.org/10.1101/2023.01.03.23284167
Diminished responses to mRNA-based SARS-CoV-2 vaccines in individuals with rheumatoid arthritis on immune modifying therapies
Samuel D. Klebanoff, Lauren B. Rodda, Chihiro Morishima, Mark H. Wener, Yevgeniy Yuzefpolskiy, Estelle Bettelli, Jane H. Buckner, Cate Speake, Marion Pepper, Daniel J. Campbell
medRxiv 2023.01.03.23284167; doi: https://doi.org/10.1101/2023.01.03.23284167
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (668)
- Allergy and Immunology (668)
- Anesthesia (181)
- Cardiovascular Medicine (2648)
- Dermatology (223)
- Emergency Medicine (399)
- Epidemiology (12228)
- Forensic Medicine (10)
- Gastroenterology (759)
- Genetic and Genomic Medicine (4103)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2657)
- Health Policy (1005)
- Hematology (363)
- HIV/AIDS (851)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (436)
- Neurology (3882)
- Nursing (209)
- Nutrition (577)
- Oncology (2030)
- Ophthalmology (585)
- Orthopedics (240)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1115)
- Primary Care Research (452)
- Public and Global Health (6527)
- Radiology and Imaging (1403)
- Respiratory Medicine (871)
- Rheumatology (409)
- Sports Medicine (342)
- Surgery (448)
- Toxicology (53)
- Transplantation (185)
- Urology (165)